While the blood-brain barrier (BBB) serves a critical protective function, it remains one of the greatest challenges in biologic drug development. Even highly potent molecules may fail to achieve sufficient exposure in the brain to deliver meaningful therapeutic benefit, while generating excessive exposure elsewhere in the body that can lead to unwanted side effects. A well-established approach is to leverage receptor-mediated transport through the endogenous transferrin receptor (TfR1) pathway to facilitate delivery of biologics across the BBB. A pre-engineered panel of TfR1-binding VHH molecules with distinct affinity profiles is available to help determine the optimal balance between receptor engagement, BBB transport, and brain exposure for your therapeutic. Unlock your CNS access with affinity-tunable TfR1-targeting VHH binders designed to enable active transport of biologics across the blood–brain barrier.
Latest briefing from the Knowledge Center